Align Technology Inc ALGN S
July 11, 2008 - 11:52am EST by
jared890
2008 2009
Price: 10.54 EPS
Shares Out. (in M): 0 P/E
Market Cap (in $M): 733 P/FCF
Net Debt (in $M): 0 EBIT 0 0
TEV ($): 0 TEV/EBIT
Borrow Cost: NA

Sign up for free guest access to view investment idea with a 45 days delay.

 

Description

Align Technology, Inc (NASDAQ: ALGN) designs, manufactures and markets the Invisalign System, a method for treating malocclusion, the misalignment of teeth. The Invisalign system corrects malocclusion through a series of clear, removable appliances that move teeth to a desired final position.

 

ALGN is a company that produces a single product with a high ASP and is very discretionary. The company has issued heavily back end loaded guidance which implicitly assumes a recovery in the consumer. While not key to our thesis, a new competitor has entered the market with a perfect substitute priced materially below the Invisalign system. We believe that ALGN will have trouble meeting guidance is likely to disappoint street expectations.

 

This is not the time for highly discretionary consumer purchases. LCA-Vision Inc (NASDAQ: LCAV), which operates laser vision correction centers, is down 91% from its peak on 7/5/2007 and trades at 6.3x forward earnings. Mentor Corp (NYSE: MNT), which makes a broad array of plastic surgery products, is down 45% from its peak on 8/7/2007 and trades at 18.5x forward earnings. ALGN is priced at 25.7x forward P/E, 2x EV / Sales and 13.2x EV / EBITDA. We value ALGN at $8.00, or 24% below current the current price, which we base on a 26x our forward earnings and 1.5x EV/Sales.

 

The Product

 

ALGN has a fundamentally good product that addresses the adult malocclusion market. Prior to ALGN, adults with crooked teeth had the option of metal braces or crooked teeth. The system works by a doctor taking an impression of a patient’s teeth and sending that impression to ALGN. ALGN then creates a series of up to 64 “aligners” that are worn for periods of two weeks at a time to slowly correct crooked teeth. The product is particularly appealing to dentists as this allows dentist to capture a revenue stream that hitherto only orthodontists received.

 

The system had a blended ASP to the dentist of $1,386 per case in 1q08. The retail price for consumers is between $4,500 to $6,000. Importantly, almost no insurance plans cover the Invisalign system leaving the company exposed to the consumers’ appetite and ability to spend their declining disposable income. Sales of the product are primarily advertising driven.

 

The Bull Case

 

The sell-side estimates that malocclusion affects 2/3 of the US population and that the addressable market is potentially 1-2% or 1-2 million people per year. In 2007, ALGN shipped 202,880 cases, i.e., the street believes that ALGN can grow significantly from the market penetration the US in addition to growth in international markets.

 

 

2004A

2005A

2006A

2007A

 

1Q08A

 

 

 

 

 

 

 

 

Total # trained practitioners

 

 

 

 

 

 

 

Orthodontists

 

7,500

7,650

8,000

8,185

 

8,410

GPs

 

12,733

16,325

20,375

25,390

 

28,630

Number of cases

 

 

 

 

 

 

 

U.S. Orthodontists

 

50,800

46,972

41,880

60,420

 

14,500

U.S. GPs

 

40,900

53,075

52,910

84,100

 

20,900

Invisalign Express

 

0

9,653

36,480

30,710

 

8,170

International

 

8,600

13,250

18,610

27,650

 

8,200

Total cases shipped

 

100,300

122,950

149,880

202,880

 

51,770

% growth

 

 

22.6%

21.9%

35.4%

 

15.0%

Average revenue / case

 

 

 

 

 

 

 

Orthodontists

 

$1,635

$1,743

$1,394

$1,341

 

$1,412

GPs

 

$1,490

1,591

1,455

1,439

 

1,487

Invisalign Express

 

 

750

750

750

 

750

International

 

$1,871

1,731

1,701

1,673

 

1,719

Blended ASP (including Express)

 

$1,596

$1,598

$1,297

$1,338

 

$1,386

Blended ASP (excluding Express)

 

$1,596

$1,671

$1,473

$1,442

 

$1,505

 

 

 

 

 

 

 

 

Revenue by channel ($mm)

 

 

 

 

 

 

 

Orthodontists

 

$83.1

$84.7

$68.6

$90.3

 

$22.8

GPs

 

60.9

88.9

93.8

134.5

 

34.8

International

 

16.1

22.9

32.0

46.6

 

14.2

Total product revenue1

 

$160.1

$196.5

$194.4

$271.4

 

$71.8

 

 

 

 

 

 

 

 

Case Refinement / other ($mm)

 

4.3

1.3

0.2

0.0

 

0.0

Freight, Training &  Equipment

 

8.5

9.3

11.8

12.9

 

3.0

Total Revenue

 

$172.8

$207.1

$206.4

$284.3

 

$74.8

 

 

 

2004

2005

2006

2007A

U.S. InvisAlign Revenue

 

147.9

174.6

162.5

224.8

Int'l InvisAlign Revenue

 

16.4

23.2

32.1

46.6

Other

 

8.5

9.3

11.8

12.9

Total Sales

 

172.8

207.1

206.4

284.3

 

 

 

 

 

 

Cost of Sales

 

56.2

63.8

64.8

75.0

Gross Profit

 

116.6

143.3

141.6

209.3

 

 

 

 

 

 

Sales and Marketing

 

55.3

80.1

82.0

98.2

R&D

 

14.4

18.6

18.5

25.7

General & Administrative

 

31.1

42.2

64.3

54.9

Operating Income

 

15.8

2.4

(23.2)

33.9

 

 

 

 

 

 

Other Income (Expense), Net

 

(0.0)

0.3

3.4

3.1

Pretax Income

 

15.8

2.7

(19.8)

37.0

 

 

 

 

 

 

Tax Expense

 

1.0

1.3

0.8

1.2

Net Income

 

14.8

1.4

(20.6)

35.7

Fully-Taxed Net Income ex-SBC

 

 

 

 

29.7

 

 

 

 

 

 

Diluted EPS

 

$0.23

$0.02

($0.33)

$0.50

Diluted EPS (adjusted)

 

 

 

 

$0.45

Fully-Taxed EPS ex-SBC

 

 

 

 

$0.42

 

 

The Bear Case

 

This is a big-ticket, discretionary purchase that a consumer makes when he wants to look better. Although ALGN was able to grow revenue in the 2001-2002 downturn, this was primarily through market expansion. Beginning in 2000, ALGN moved from primarily an orthodontist distributed company into the general practitioner dental channel. However, the company missed nearly every estimate thrown its way as utilization rates at doctors declined. The stock declined from $18.06 on 1/29/2001 to a low of $1.30 on 11/13/2002.

 

Unfortunately, ALGN has largely penetrated the dentist channel in the last 6 years and international revenue (16% of total revenue; mostly Western Europe) is too small to provide the same boost as the GP dentist channel did in 2001-2002 time frame.

 

A high percent of purchases are financed. Although the company and the street admit they do not have accurate data on the financing, former ALGN sales reps admit that part of their pitch to doctors was that if a patient said the he could not afford the system then to tell the patient to put the purchase on a home equity line of credit (HELOC); banks are slashing HELOCs at unprecended rates do to problems in the housing market. The largest dental lender in the space is GE’s CareCredit subsidiary; GE is drawing back on its consumer lending due to internal problems. According to the latest Senior Loan Officer Opinion survey by the Federal Reserve and almost every newspaper we read, access to consumer credit is being tightened across the board.

 

Management’s guidance is significantly back end loaded and implicitly relies on a recovery in discretionary consumer spending. Management is expecting FY2008 revenue of between $320 to 330 million, up 13% to 16% year-over-year. However, guidance for FY2q08 is only $78.8 to 81.5 million, up 4% year-over-year. This guidance implies that ALGN will be able to grow revenue by 18% year-over-year in the second half of 2008 despite an increasingly strained consumer.

 

On top of this, ALGN has guided that it will spend ahead on its advertising in 2q08 in order to secure lower rates before the presidential election advertising and the Olympic advertising begin in earnest. This is why ALGN is guiding for such low EPS in 2q08 of 4-6c v prior street estimates of 12c. We can understand this from a business perspective but we have difficult reconciling this EPS guidance with revenue guidance. Consumer demand is advertising driven. How can ALGN have a large increase in spending with anemic sales growth in 2q08 followed by a large decrease in advertising concomitant with 18% sales growth in 2h08?

 

From this fact pattern, we believe there is a high probability that ALGN misses sales and earnings estimates in 3q08 and 4q08.

 

 

New Competition

 

ClearCorrect Systems initiated a general launch for its products in late May. Prior to this point, ClearCorrect was only offered through a limited number of dentists. According to the FTN Midwest note from July 10, 2008, ClearCorrect is initially focusing its doctor recruitment efforts in the Southwest US. ClearCorrect is competing on price by offering doctor’s between ¼ to 1/3 off of ALGN prices.

 

 

ALGN Price

ClearConnect Price

Full Product

$1,340-1,495

$995

Limited Product

$750

$595

Retainers

$95

$275

 

Doctors don’t appear to have a high degree of loyalty to the ALGN system and there are not large switching costs.

  • Loyalty: between 2004-2006, ALGN lost market share to Orthoclear, a company founded by a disgruntled former ALGN employee, that competed primarily on price.
  • Switching costs: for either ALGN or a competitor, a doctor simply takes a mould of the patient’s teeth and sends that mold to the company to make a series of teeth trays).

 

Valuation

 

ALGN has traded well below 1.5 EV/Sales twice in the past:

·         In 2002 when utilization rates dropped due to the 2001-2002 recession.

·         In 2005 when ALGN was competing against Orthoclear for market share.

 

Given that the consumer headwinds facing ALGN are at least as severe in the 2001-2002 recession and that ALGN is facing a competitor, we feel that ALGN should trade no more than 1.5 EV / Sales. This would imply a share price of no more than $8.10.

 

The street is willing to pay 26x 2008 the consensus estimate of 40c. Giving the company the benefit of the doubt, ALGN might be able to earn 30c this year. Assuming no multiple contraction whatsoever, this would imply a price of $7.80.

 

Taking an average of these two methods, we believe that ALGN should be valued at no more than $8.00.

 

Risks

 

·         Takeout risk: takeouts in the healthcare sector are historically between 4-7x trailing sales. We view this risk as somewhat mitigated by short life of ALGN’s patents (7-8 years) and the ease with which two competitors – Orthoclear and ClearConncet Systems – have had with engineering perfect substitutes to the Invisalign System.

·         Economic recovery: ALGN may well outperform expectations to the extent that large-ticket, consumer-discretionary purchases recovery.

·         Patents: ALGN successfully leverage its IP in the legal system to

·         International expansion: International revenue constituted 16% of revenue and international revenue grew 32% year-over-year. To the extent that ALGN is successful in penetrating new markets, the company may be successful in offsetting weakness in the US.

 

Catalysts

 

·         Earnings disappoint.

·         Success of ClearConnect’s product.

Catalyst

· Earnings disappoint.

· Success of ClearConnect’s product.
    sort by   Expand   New

    Description

    Align Technology, Inc (NASDAQ: ALGN) designs, manufactures and markets the Invisalign System, a method for treating malocclusion, the misalignment of teeth. The Invisalign system corrects malocclusion through a series of clear, removable appliances that move teeth to a desired final position.

     

    ALGN is a company that produces a single product with a high ASP and is very discretionary. The company has issued heavily back end loaded guidance which implicitly assumes a recovery in the consumer. While not key to our thesis, a new competitor has entered the market with a perfect substitute priced materially below the Invisalign system. We believe that ALGN will have trouble meeting guidance is likely to disappoint street expectations.

     

    This is not the time for highly discretionary consumer purchases. LCA-Vision Inc (NASDAQ: LCAV), which operates laser vision correction centers, is down 91% from its peak on 7/5/2007 and trades at 6.3x forward earnings. Mentor Corp (NYSE: MNT), which makes a broad array of plastic surgery products, is down 45% from its peak on 8/7/2007 and trades at 18.5x forward earnings. ALGN is priced at 25.7x forward P/E, 2x EV / Sales and 13.2x EV / EBITDA. We value ALGN at $8.00, or 24% below current the current price, which we base on a 26x our forward earnings and 1.5x EV/Sales.

     

    The Product

     

    ALGN has a fundamentally good product that addresses the adult malocclusion market. Prior to ALGN, adults with crooked teeth had the option of metal braces or crooked teeth. The system works by a doctor taking an impression of a patient’s teeth and sending that impression to ALGN. ALGN then creates a series of up to 64 “aligners” that are worn for periods of two weeks at a time to slowly correct crooked teeth. The product is particularly appealing to dentists as this allows dentist to capture a revenue stream that hitherto only orthodontists received.

     

    The system had a blended ASP to the dentist of $1,386 per case in 1q08. The retail price for consumers is between $4,500 to $6,000. Importantly, almost no insurance plans cover the Invisalign system leaving the company exposed to the consumers’ appetite and ability to spend their declining disposable income. Sales of the product are primarily advertising driven.

     

    The Bull Case

     

    The sell-side estimates that malocclusion affects 2/3 of the US population and that the addressable market is potentially 1-2% or 1-2 million people per year. In 2007, ALGN shipped 202,880 cases, i.e., the street believes that ALGN can grow significantly from the market penetration the US in addition to growth in international markets.

     

     

    2004A

    2005A

    2006A

    2007A

     

    1Q08A

     

     

     

     

     

     

     

     

    Total # trained practitioners

     

     

     

     

     

     

     

    Orthodontists

     

    7,500

    7,650

    8,000

    8,185

     

    8,410

    GPs

     

    12,733

    16,325

    20,375

    25,390

     

    28,630

    Number of cases

     

     

     

     

     

     

     

    U.S. Orthodontists

     

    50,800

    46,972

    41,880

    60,420

     

    14,500

    U.S. GPs

     

    40,900

    53,075

    52,910

    84,100

     

    20,900

    Invisalign Express

     

    0

    9,653

    36,480

    30,710

     

    8,170

    International

     

    8,600

    13,250

    18,610

    27,650

     

    8,200

    Total cases shipped

     

    100,300

    122,950

    149,880

    202,880

     

    51,770

    % growth

     

     

    22.6%

    21.9%

    35.4%

     

    15.0%

    Average revenue / case

     

     

     

     

     

     

     

    Orthodontists

     

    $1,635

    $1,743

    $1,394

    $1,341

     

    $1,412

    GPs

     

    $1,490

    1,591

    1,455

    1,439

     

    1,487

    Invisalign Express

     

     

    750

    750

    750

     

    750

    International

     

    $1,871

    1,731

    1,701

    1,673

     

    1,719

    Blended ASP (including Express)

     

    $1,596

    $1,598

    $1,297

    $1,338

     

    $1,386

    Blended ASP (excluding Express)

     

    $1,596

    $1,671

    $1,473

    $1,442

     

    $1,505

     

     

     

     

     

     

     

     

    Revenue by channel ($mm)

     

     

     

     

     

     

     

    Orthodontists

     

    $83.1

    $84.7

    $68.6

    $90.3

     

    $22.8

    GPs

     

    60.9

    88.9

    93.8

    134.5

     

    34.8

    International

     

    16.1

    22.9

    32.0

    46.6

     

    14.2

    Total product revenue1

     

    $160.1

    $196.5

    $194.4

    $271.4

     

    $71.8

     

     

     

     

     

     

     

     

    Case Refinement / other ($mm)

     

    4.3

    1.3

    0.2

    0.0

     

    0.0

    Freight, Training &  Equipment

     

    8.5

    9.3

    11.8

    12.9

     

    3.0

    Total Revenue

     

    $172.8

    $207.1

    $206.4

    $284.3

     

    $74.8

     

     

     

    2004

    2005

    2006

    2007A

    U.S. InvisAlign Revenue

     

    147.9

    174.6

    162.5

    224.8

    Int'l InvisAlign Revenue

     

    16.4

    23.2

    32.1

    46.6

    Other

     

    8.5

    9.3

    11.8

    12.9

    Total Sales

     

    172.8

    207.1

    206.4

    284.3

     

     

     

     

     

     

    Cost of Sales

     

    56.2

    63.8

    64.8

    75.0

    Gross Profit

     

    116.6

    143.3

    141.6

    209.3

     

     

     

     

     

     

    Sales and Marketing

     

    55.3

    80.1

    82.0

    98.2

    R&D

     

    14.4

    18.6

    18.5

    25.7

    General & Administrative

     

    31.1

    42.2

    64.3

    54.9

    Operating Income

     

    15.8

    2.4

    (23.2)

    33.9

     

     

     

     

     

     

    Other Income (Expense), Net

     

    (0.0)

    0.3

    3.4

    3.1

    Pretax Income

     

    15.8

    2.7

    (19.8)

    37.0

     

     

     

     

     

     

    Tax Expense

     

    1.0

    1.3

    0.8

    1.2

    Net Income

     

    14.8

    1.4

    (20.6)

    35.7

    Fully-Taxed Net Income ex-SBC

     

     

     

     

    29.7

     

     

     

     

     

     

    Diluted EPS

     

    $0.23

    $0.02

    ($0.33)

    $0.50

    Diluted EPS (adjusted)

     

     

     

     

    $0.45

    Fully-Taxed EPS ex-SBC

     

     

     

     

    $0.42

     

     

    The Bear Case

     

    This is a big-ticket, discretionary purchase that a consumer makes when he wants to look better. Although ALGN was able to grow revenue in the 2001-2002 downturn, this was primarily through market expansion. Beginning in 2000, ALGN moved from primarily an orthodontist distributed company into the general practitioner dental channel. However, the company missed nearly every estimate thrown its way as utilization rates at doctors declined. The stock declined from $18.06 on 1/29/2001 to a low of $1.30 on 11/13/2002.

     

    Unfortunately, ALGN has largely penetrated the dentist channel in the last 6 years and international revenue (16% of total revenue; mostly Western Europe) is too small to provide the same boost as the GP dentist channel did in 2001-2002 time frame.

     

    A high percent of purchases are financed. Although the company and the street admit they do not have accurate data on the financing, former ALGN sales reps admit that part of their pitch to doctors was that if a patient said the he could not afford the system then to tell the patient to put the purchase on a home equity line of credit (HELOC); banks are slashing HELOCs at unprecended rates do to problems in the housing market. The largest dental lender in the space is GE’s CareCredit subsidiary; GE is drawing back on its consumer lending due to internal problems. According to the latest Senior Loan Officer Opinion survey by the Federal Reserve and almost every newspaper we read, access to consumer credit is being tightened across the board.

     

    Management’s guidance is significantly back end loaded and implicitly relies on a recovery in discretionary consumer spending. Management is expecting FY2008 revenue of between $320 to 330 million, up 13% to 16% year-over-year. However, guidance for FY2q08 is only $78.8 to 81.5 million, up 4% year-over-year. This guidance implies that ALGN will be able to grow revenue by 18% year-over-year in the second half of 2008 despite an increasingly strained consumer.

     

    On top of this, ALGN has guided that it will spend ahead on its advertising in 2q08 in order to secure lower rates before the presidential election advertising and the Olympic advertising begin in earnest. This is why ALGN is guiding for such low EPS in 2q08 of 4-6c v prior street estimates of 12c. We can understand this from a business perspective but we have difficult reconciling this EPS guidance with revenue guidance. Consumer demand is advertising driven. How can ALGN have a large increase in spending with anemic sales growth in 2q08 followed by a large decrease in advertising concomitant with 18% sales growth in 2h08?

     

    From this fact pattern, we believe there is a high probability that ALGN misses sales and earnings estimates in 3q08 and 4q08.

     

     

    New Competition

     

    ClearCorrect Systems initiated a general launch for its products in late May. Prior to this point, ClearCorrect was only offered through a limited number of dentists. According to the FTN Midwest note from July 10, 2008, ClearCorrect is initially focusing its doctor recruitment efforts in the Southwest US. ClearCorrect is competing on price by offering doctor’s between ¼ to 1/3 off of ALGN prices.

     

     

    ALGN Price

    ClearConnect Price

    Full Product

    $1,340-1,495

    $995

    Limited Product

    $750

    $595

    Retainers

    $95

    $275

     

    Doctors don’t appear to have a high degree of loyalty to the ALGN system and there are not large switching costs.

     

    Valuation

     

    ALGN has traded well below 1.5 EV/Sales twice in the past:

    ·         In 2002 when utilization rates dropped due to the 2001-2002 recession.

    ·         In 2005 when ALGN was competing against Orthoclear for market share.

     

    Given that the consumer headwinds facing ALGN are at least as severe in the 2001-2002 recession and that ALGN is facing a competitor, we feel that ALGN should trade no more than 1.5 EV / Sales. This would imply a share price of no more than $8.10.

     

    The street is willing to pay 26x 2008 the consensus estimate of 40c. Giving the company the benefit of the doubt, ALGN might be able to earn 30c this year. Assuming no multiple contraction whatsoever, this would imply a price of $7.80.

     

    Taking an average of these two methods, we believe that ALGN should be valued at no more than $8.00.

     

    Risks

     

    ·         Takeout risk: takeouts in the healthcare sector are historically between 4-7x trailing sales. We view this risk as somewhat mitigated by short life of ALGN’s patents (7-8 years) and the ease with which two competitors – Orthoclear and ClearConncet Systems – have had with engineering perfect substitutes to the Invisalign System.

    ·         Economic recovery: ALGN may well outperform expectations to the extent that large-ticket, consumer-discretionary purchases recovery.

    ·         Patents: ALGN successfully leverage its IP in the legal system to

    ·         International expansion: International revenue constituted 16% of revenue and international revenue grew 32% year-over-year. To the extent that ALGN is successful in penetrating new markets, the company may be successful in offsetting weakness in the US.

     

    Catalysts

     

    ·         Earnings disappoint.

    ·         Success of ClearConnect’s product.

    Catalyst

    · Earnings disappoint.

    · Success of ClearConnect’s product.

    Messages


    SubjectNew Writeup
    Entry07/11/2008 11:53 AM
    Memberjared890
    Description:

    Align Technology, Inc (NASDAQ: ALGN) designs, manufactures and markets the Invisalign System, a method for treating malocclusion, the misalignment of teeth. The Invisalign system corrects malocclusion through a series of clear, removable appliances that move teeth to a desired final position.

     

    ALGN is a company that produces a single product with a high ASP and is very discretionary. The company has issued heavily back end loaded guidance which implicitly assumes a recovery in the consumer. While not key to our thesis, a new competitor has entered the market with a perfect substitute priced materially below the Invisalign system. We believe that ALGN will have trouble meeting guidance is likely to disappoint street expectations.

     

    This is not the time for highly discretionary consumer purchases. LCA-Vision Inc (NASDAQ: LCAV), which operates laser vision correction centers, is down 91% from its peak on 7/5/2007 and trades at 6.3x forward earnings. Mentor Corp (NYSE: MNT), which makes a broad array of plastic surgery products, is down 45% from its peak on 8/7/2007 and trades at 18.5x forward earnings. ALGN is priced at 25.7x forward P/E, 2x EV / Sales and 13.2x EV / EBITDA. We value ALGN at $8.00, or 24% below current the current price, which we base on a 26x our forward earnings and 1.5x EV/Sales.

     

    The Product

     

    ALGN has a fundamentally good product that addresses the adult malocclusion market. Prior to ALGN, adults with crooked teeth had the option of metal braces or crooked teeth. The system works by a doctor taking an impression of a patient’s teeth and sending that impression to ALGN. ALGN then creates a series of up to 64 “aligners” that are worn for periods of two weeks at a time to slowly correct crooked teeth. The product is particularly appealing to dentists as this allows dentist to capture a revenue stream that hitherto only orthodontists received.

     

    The system had a blended ASP to the dentist of $1,386 per case in 1q08. The retail price for consumers is between $4,500 to $6,000. Importantly, almost no insurance plans cover the Invisalign system leaving the company exposed to the consumers’ appetite and ability to spend their declining disposable income. Sales of the product are primarily advertising driven.

     

    The Bull Case

     

    The sell-side estimates that malocclusion affects 2/3 of the US population and that the addressable market is potentially 1-2% or 1-2 million people per year. In 2007, ALGN shipped 202,880 cases, i.e., the street believes that ALGN can grow significantly from the market penetration the US in addition to growth in international markets.

     

     

    2004A

    2005A

    2006A

    2007A

     


    SubjectNew Writeup
    Entry07/11/2008 11:54 AM
    Memberjared890
    Please disregard the "New Writeup" in the message board. I hit submit twice and the "New Writeup" was automatically generated as a result.

    SubjectRE: Dentist Penetration
    Entry07/14/2008 03:01 PM
    Memberjared890
    Most general practitioner dentists are not comfortable doing orthodontics. While ALGN is likely to increase its general practitioner base by a few hundred dentists each year, ALGN has already identified and penetrated the cohort of general practitioner dentists who are most comfortable with selling this product.

    Anecdotally, my dentist, who is in a high volume location in a major metro, refers patients asking for Invisalign to an orthodontist. Given his scale, he could easily add Invisalign to his product offering and capture the revenue stream he refers to an orthodontist but chooses not to.

    SubjectRE: Switching costs and compet
    Entry07/14/2008 03:14 PM
    Memberjared890
    The training session takes a weekend. While a doctor switching to ClearConnect from ALGN would likely have to repeat this training, it is not a very large switching cost.

    Traditional braces are generally $1,000 or more cheaper than the Invisalign system. A dentist could choose to lower the retail price but this would come at a direct cost to the dentist’s profit.

    Orthoclear is no longer in business. The company was created by one of the former founders of ALGN who became disaffected when ALGN moved production from Pakistan after Sept 11, 2001; this founder was of Pakistani descent. In 2006 ALGN paid Orthoclear 20 million to close shop and stop competing in this market.

    SubjectRE: RE: Switching costs and co
    Entry07/14/2008 04:11 PM
    Memberheffer504
    where do you find the data on clearconnect? not much is immediately evident on the internet.

    SubjectRE: RE: RE: Switching costs an
    Entry07/14/2008 05:39 PM
    Membergreenshoes93
    Given the barriers to becoming a dentist, there's obviously an opportunity cost to doing one procedure over another. Have you thought at all about the hourly wage of a dentist doing typical cleanings and whitenings vs. the time spent on Invisalign to get a sense of how much price points can potentially shift downwards in an economic downturn but still be cost effective for a dentist to sell the product, assuming ASP to ALGN doesn't change? If it's meaningfully lower, ALGN's volumes might be preserved even in a downturn in consumer discretionary, where the dentist is bearing the margin contraction.

    Subjectclearconnect
    Entry07/17/2008 09:45 PM
    Memberelke528
    Can you please direct me to the URL for ClearConnect? I can't find it anywhere on the Internet.

    SubjectRE: clearconnect
    Entry07/18/2008 10:10 AM
    Memberjared890
    ClearCorrect's website http://clearcorrect.com/ is still under construction. They have a promo video available on YouTube http://www.youtube.com/watch?v=Zbhy0RVkiX0.

    FTN Midwest published a research note on July 10, 2008 which discusses ClearCorrect marketing strategy. To quote from that report: "Our contacts suggest ClearCorrect uses a scalable manufacturing process and the company has partnered with an established software company to develop its treatment planning software" and "Our contacts indicate ClearCorrect has hired several sales reps and
    is actively recruiting doctors for its certification courses. We believe ClearCorrect is initially focusing its doctor recruitment efforts in the Southwest United States." The report lays out in full ClearCorrect's pricing.


    SubjectCompetition and New Products
    Entry07/18/2008 11:02 AM
    Membernantembo629
    Hi Thanks for the writeup I have a few questions : 1) Is Clearcorrect a viable competitor -- Have you been able to speak with anyone at the company? I have only been able to find a youtube video on the product. Furthermore, from what I understand the production process here is fully manual process and not as scalable as Align. So how does this affect switching costs and then how much impact do you think Clearcorrect can have? 2) From what I understand, Orthoclear is out of business and Align has purchased all of their patents. How does this affect Align's capabilities to fend off encroaching competition? Also, does Clear Correct infringe Align's patents? 3) I have heard ALGN is launching new products. What do you think of these new products? How will this affect the growth and margins? 4)Why did the ASP increase so much in the 1q 2008? Is this sustainable?
      Back to top